Fluothane Solution

Induction and maintenance of general anaesthesia

Inhalation Induction and maintenance of general anaesthesia Adult: Induction: 0.5% v/v of halothane in oxygen or mixture of nitrous oxide and oxygen, increase gradually according to response to a concentration of 2-4% v/v. Maintenance: 0.5-2% v/v depending on the flow rate used.

Inhalation Induction and maintenance of general anaesthesia Child: Induction: 1.5-2% v/v. Maintenance: 0.5-1.5% v/v.

Known or suspected susceptibility to malignant hyperthermia, raised CSF pressure, history of unexplained jaundice or acute hepatic damage from previous exposure to halothane. Childn <18 yr undergoing outpatient dental surgery.

Patient w/ phaeochromocytoma, myasthenia gravis, renal failure, pre-existing hepatic disease. Childn. Pregnancy and lactation. Patient Counselling May impair ability to drive or operate machinery. Monitoring Parameters Monitor pulse and BP.

C

Increased risk of ventricular dysrhythmias w/ epinephrine. Increased risk of malignant hyperthermia w/ suxamethonium. Prolonged recovery from anaesth w/ concurrent use of ketamine for induction. May potentiate response to non-depolarising muscle relaxants, hypotensive agents (e.g. hexamethonium bromide, trimetaphan camsilate).

Post-op nausea, vomiting, and shivering; resp depression, hypotension, skeletal muscle relaxation, bradycardia. Potentially Fatal: Hepatotoxicity, malignant hyperthermia, cardiac arrhythmias.

Halothane is a potent non-flammable inhalational anaesth which depresses both cerebral function and sympathetic activity. It suppresses salivary, bronchial and gastric secretions and dilates the bronchioles.

Fluothane Solution manufactured by Astrazeneca Pharmaceutical company. Its generic name is Halothane.